Genmab — Februar 2021
-
fair enough @troldmanden , i think we probably agree on the strategy. I would expect analysts to look through short term bottom line though, and understand that the earlier we take these investment costs, the sooner we can reap the potential rewards
-
Det kunne godt lugte lidt af noget revaluation
-
På en trist dag er det godt at have Jan - https://borsen.dk/nyheder/virksomheder/jan-van-de-winkel-forudser-tredobling-af-genmabs-vaerdi
-
Så nu kan vi godt stoppe med at tale om 3000 - vi skal til at tale om 6000
-
Ukuelige Jan

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
